Innovative Vaccine Design Uses Deformable Adjuvants to Boost Immunity

A research team led by Prof. Xia Yufei from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences has made significant strides in vaccine development by enhancing immune activation through innovative adjuvant design. Published on January 8, 2026, in the journal Cell Biomaterials, the study reveals that redesigning conventional aluminum adjuvants into a deformable, three-dimensional interface can markedly improve immune responses, particularly in elderly or low-responsive populations.

Traditional vaccine adjuvants primarily rely on molecular binding and biochemical stimulation to activate the immune system. However, these methods often yield limited efficacy, especially in aging individuals. The challenge has been to effectively introduce physical regulation into immune activation processes. The new approach taken by the researchers involves the construction of aluminum-stabilized Pickering emulsions (ASPEs). These emulsions enable dendritic cells (DCs) to engage actively with mechanical cues at the interface, leading to a significant boost in immune responses.

The ASPE droplets deform upon contact with DC membranes, which increases the interfacial contact area and delivers precise mechanical stress. By adjusting the crystallinity of aluminum nanoparticles, the researchers can regulate the interfacial stiffness, allowing for controlled mechanical stimulation. This is particularly important as stronger mechanical cues activate the mechanosensitive ion channel PIEZO1, triggering a calcium influx that promotes antigen cross-presentation.

In a notable advancement, when the ASPE platform is combined with the TLR4 agonist monophosphoryl lipid A (MPLA), it achieves a synergistic effect. The results indicate that the ASPE-M formulation induces stronger dendritic cell maturation compared to the conventional Alum+MPLA formulation. Additionally, it enhances Th1-biased immunity and elicits robust responses from CD8+ T-cells.

The effectiveness of this innovative approach is particularly pronounced in aged mouse models, where it significantly improves therapeutic outcomes in dendritic cell-based melanoma immunotherapy. The synergy with PD-1 blockade further amplifies these benefits, suggesting a promising avenue for enhancing immunotherapy in challenging patient populations.

Overall, this research establishes that interfacial mechanics play a critical role in immune regulation, complementing traditional biochemical signaling methods. The findings present a new strategy for vaccine and immunotherapy design, with significant potential for improving immune efficacy in aging and immunocompromised populations.

For further details on this study, refer to the original publication: Yali Ming et al., “Drilling dendritic cell activation: Engineering interfacial mechano-biochemical cues for enhanced immunotherapy,” in Cell Biomaterials (2025). DOI: 10.1016/j.celbio.2025.100281.